DXCM
Price
$84.89
Change
-$2.45 (-2.81%)
Updated
May 21 closing price
Capitalization
53.47B
63 days until earnings call
RMD
Price
$245.78
Change
-$2.36 (-0.95%)
Updated
May 21 closing price
Capitalization
29.13B
70 days until earnings call
Interact to see
Advertisement

DXCM vs RMD

Header iconDXCM vs RMD Comparison
Open Charts DXCM vs RMDBanner chart's image
DexCom
Price$84.89
Change-$2.45 (-2.81%)
Volume$2.67M
Capitalization53.47B
ResMed
Price$245.78
Change-$2.36 (-0.95%)
Volume$847.1K
Capitalization29.13B
DXCM vs RMD Comparison Chart
Loading...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DXCM vs. RMD commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a Buy and RMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (DXCM: $84.89 vs. RMD: $245.78)
Brand notoriety: DXCM and RMD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: DXCM: 59% vs. RMD: 75%
Market capitalization -- DXCM: $53.47B vs. RMD: $29.13B
DXCM [@Medical Specialties] is valued at $53.47B. RMD’s [@Medical Specialties] market capitalization is $29.13B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DXCM’s FA Score shows that 0 FA rating(s) are green whileRMD’s FA Score has 2 green FA rating(s).

  • DXCM’s FA Score: 0 green, 5 red.
  • RMD’s FA Score: 2 green, 3 red.
According to our system of comparison, RMD is a better buy in the long-term than DXCM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DXCM’s TA Score shows that 5 TA indicator(s) are bullish while RMD’s TA Score has 5 bullish TA indicator(s).

  • DXCM’s TA Score: 5 bullish, 4 bearish.
  • RMD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both DXCM and RMD are a good buy in the short-term.

Price Growth

DXCM (@Medical Specialties) experienced а -1.88% price change this week, while RMD (@Medical Specialties) price change was -0.49% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.07%. For the same industry, the average monthly price growth was +6.40%, and the average quarterly price growth was -0.60%.

Reported Earning Dates

DXCM is expected to report earnings on Jul 24, 2025.

RMD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (+0.07% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DXCM($53.5B) has a higher market cap than RMD($29.1B). DXCM has higher P/E ratio than RMD: DXCM (106.11) vs RMD (31.34). DXCM YTD gains are higher at: 9.155 vs. RMD (7.948). RMD has higher annual earnings (EBITDA): 1.43B vs. DXCM (917M). DXCM has more cash in the bank: 2.72B vs. RMD (210M). RMD has less debt than DXCM: RMD (1.39B) vs DXCM (2.59B). RMD has higher revenues than DXCM: RMD (4.5B) vs DXCM (3.62B).
DXCMRMDDXCM / RMD
Capitalization53.5B29.1B184%
EBITDA917M1.43B64%
Gain YTD9.1557.948115%
P/E Ratio106.1131.34339%
Revenue3.62B4.5B80%
Total Cash2.72B210M1,297%
Total Debt2.59B1.39B186%
FUNDAMENTALS RATINGS
DXCM vs RMD: Fundamental Ratings
DXCM
RMD
OUTLOOK RATING
1..100
239
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
9856
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4523
P/E GROWTH RATING
1..100
7970
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RMD's Valuation (18) in the Medical Specialties industry is somewhat better than the same rating for DXCM (83). This means that RMD’s stock grew somewhat faster than DXCM’s over the last 12 months.

RMD's Profit vs Risk Rating (56) in the Medical Specialties industry is somewhat better than the same rating for DXCM (98). This means that RMD’s stock grew somewhat faster than DXCM’s over the last 12 months.

RMD's SMR Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that RMD’s stock grew similarly to DXCM’s over the last 12 months.

RMD's Price Growth Rating (23) in the Medical Specialties industry is in the same range as DXCM (45). This means that RMD’s stock grew similarly to DXCM’s over the last 12 months.

RMD's P/E Growth Rating (70) in the Medical Specialties industry is in the same range as DXCM (79). This means that RMD’s stock grew similarly to DXCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DXCMRMD
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
63%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
62%
Momentum
ODDS (%)
Bullish Trend 7 days ago
65%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
58%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 4 days ago
63%
Declines
ODDS (%)
Bearish Trend 7 days ago
72%
Bearish Trend 1 day ago
60%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
68%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMH37.91-0.69
-1.79%
American Homes 4 Rent
UNB31.00-1.00
-3.12%
Union Bankshares
HFWA23.15-0.86
-3.58%
Heritage Financial Corp
AEON0.49-0.02
-4.46%
AEON Biopharma
LGIH52.56-2.95
-5.31%
LGI Homes

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then CERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-2.81%
CERS - DXCM
42%
Loosely correlated
-6.72%
RMD - DXCM
35%
Loosely correlated
-0.95%
IRMD - DXCM
34%
Loosely correlated
-0.15%
PEN - DXCM
33%
Loosely correlated
-3.82%
ACRS - DXCM
33%
Loosely correlated
-4.44%
More

RMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RMD has been loosely correlated with INSP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then INSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RMD
1D Price
Change %
RMD100%
-0.95%
INSP - RMD
40%
Loosely correlated
-2.64%
RVTY - RMD
39%
Loosely correlated
-4.01%
IDXX - RMD
38%
Loosely correlated
-3.15%
ALGN - RMD
34%
Loosely correlated
-5.84%
DXCM - RMD
34%
Loosely correlated
-2.81%
More